Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7757887 | 0.77 | ALDH1A1 (0.33) | — | |
| SCHEMBL5136305 | 0.77 | NR5A1 (0.37) | — | |
| SCHEMBL29963693 | 0.76 | TP53 (0.38) | KCNH3GAA | |
| SCHEMBL3613137 | 0.75 | KCNH3 (0.36) | KCNH3 | |
| SCHEMBL10442226 | 0.74 | KCNH3 (0.37) | KCNH3GAA | |
| Ethane SCHEMBL11766692 | 0.74 | KCNH3 (0.47) | KCNH3GAA | |
| SCHEMBL16637760 | 0.74 | MAPT (0.46) | GAA | |
| Hydrochloric Acid SCHEMBL28313389 | 0.74 | KCNH3 (0.51) | KCNH3GAA | |
| SCHEMBL1031467 | 0.73 | — | — | |
| SCHEMBL2026345 | 0.73 | TDP1 (0.46) | KCNH3GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8969552-B2 | Arylsulfonylmethyl or arylsulfonamide substituted aromatic compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-03-03 | — | — | US | disclosed |
| EP-2439203-B1 | Arylsulfonylmethyl or arylsulfonamide substituted aromatic compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor | ABBVIE DEUTSCHLAND (DE) | 2014-11-19 | — | — | EP | disclosed |
| EP-1812416-B1 | ARYLSULFONYLMETHYL OR ARYLSULFONAMIDE SUBSTITUTED AROMATIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR | ABBOTT GMBH & CO KG (DE) | 2013-08-21 | — | — | EP | disclosed |
| US-8497273-B2 | Heterocyclic compounds suitable for treating disorders that respond to modulation of the serotonin 5HT6 receptor | ABBOTT GMBH & CO. KG (DE) | 2013-07-30 | — | — | US | disclosed |
| US-8486984-B2 | Aminomethyl substituted bicyclic aromatic compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor | ABBOTT GMBH & CO., KG (DE) | 2013-07-16 | — | — | US | disclosed |
| US-8470810-B2 | Heterocyclic compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor | ABBOTT GMBH & CO. KG (DE) | 2013-06-25 | — | — | US | disclosed |
| US-8383641-B2 | Aryloxyethylamine compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor | ABBOTT GMBH & CO. KG (DE) | 2013-02-26 | — | — | US | disclosed |
| US-20120220635-A1 | AMINOETHYLAROMATIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2012-08-30 | — | — | US | disclosed |
| US-8232426-B2 | N-[4-((S)-2-Propylamino-propyl)-phenyl]-4-trifluoromethoxy-benzenesulfonamide; Dipropyl-{2-[4-(4-trifluoromethoxy-benzenesulfonylmethyl)-phenyl]-ethyl}-dipropyl-amine salt, psychological, nervous system disorders such as schizophernia, bipolar, dyskinesias, tourette syndrome, depression, sleep disorder | ABBOTT GMBH & CO. KG (DE) | 2012-07-31 | — | — | US | disclosed |
| EP-1809597-B1 | AMINOETHYLAROMATIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR | ABBOTT GMBH & CO KG (DE) | 2012-01-11 | — | — | EP | disclosed |
| US-20080045493-A1 | Heterocyclic Compounds Suitable For Treating Disorders That Respond To Modulation Of The Dopamine D3 Receptor | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2008-02-21 | — | — | US | disclosed |
| WO-2007118900-A1 | HETEROCYCLIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5HT6 RECEPTOR | ABBOTT GMBH & CO. KG (DE) | 2007-10-25 | — | — | WO | disclosed |
| EP-1814849-A1 | HETEROCYCLIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR | Abbott GmbH & Co. KG (DE) | 2007-08-08 | — | — | EP | disclosed |
| WO-2006040182-A1 | HETEROCYCLIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR | ABBOTT GMBH & CO. KG (DE) | 2006-04-20 | — | — | WO | disclosed |
| US-4122062-A | FILLERS | KENRICH PETROCHEMICALS, INC. (US) | 1978-10-24 | — | — | US | disclosed |
| US-4098758-A | ORGANIC ACIDS, FOR USE IN POLYMER SYSTEMS | KENRICH PETROCHEMICALS, INC. (US) | 1978-07-04 | — | — | US | disclosed |
| US-4096110-A | Filled polyesters containing organic titanate esters | KENRICH PETROCHEMICALS, INC. (US) | 1978-06-20 | — | — | US | disclosed |
| US-4094853-A | Alkoxy titanate salts useful as coupling agents | KENRICH PETROCHEMICALS, INC. (US) | 1978-06-13 | — | — | US | disclosed |
| US-4087402-A | USED FOR TREATMENT OF INORGANIC FILLERS | KENRICH PETROCHEMICALS, INC. (US) | 1978-05-02 | — | — | US | disclosed |
| US-4069192-A | ORGANIC | KENRICH PETROCHEMICALS, INC. (US) | 1978-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045493-A1 | Heterocyclic Compounds Suitable For Treating Disorders That Respond To Modulation Of The Dopamine D3 Receptor | DRD3, MC3R, CHRNA3 | KCNH3 526/4885GAA 4437/4885 |
| US-20120220635-A1 | AMINOETHYLAROMATIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR | SLC6A3, ADRB3, DRD3 | KCNH3 1173/4885GAA 928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.